共 193 条
[1]
Wouters OJ(2020)Estimated research and development investment needed to bring a new medicine to market, 2009-2018 JAMA. 323 844-33
[2]
McKee M(2016)Innovation in the pharmaceutical industry: new estimates of R&D costs J Health Econ 47 20-166
[3]
Luyten J(2014)Prevalence, characteristics, and publication of discontinued randomized trials JAMA. 311 1045-2711
[4]
DiMasi JA(2014)Recruitment of participants to a multiple sclerosis trial: the CombiRx experience Clin Trials 11 159-928
[5]
Grabowski HG(2010)Addressing the challenges to successful recruitment and retention in Alzheimer’s disease clinical trials Alzheimers Res Ther 2 34-152
[6]
Hansen RW(2017)Early termination of cardiovascular trials as a consequence of poor accrual: analysis of ClinicalTrials.gov 2006–2015 BMJ Open 7 e013482-128
[7]
Kasenda B(2000)What makes clinical research ethical? JAMA. 283 2701-2388
[8]
von Elm E(1997)Eligibility of Alzheimer’s disease clinic patients for clinical trials J Am Geriatr Soc 45 923-563
[9]
You J(2021)Representativeness of participants eligible to be enrolled in clinical trials of aducanumab for Alzheimer disease compared with medicare beneficiaries with Alzheimer disease and mild cognitive impairment JAMA. 326 1627-1783
[10]
Blümle A(2018)Lessons learned from Alzheimer disease: clinical trials with negative outcomes: lessons learned from Alzheimer disease Clin Transl Sci 11 147-861